GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GSK and Gilead Sciences received multiple approvals for pipeline products and benchmarked performance against competitors.Sub-event
- FDA grants Gilead accelerated approval while GSK and EXEL advance PBC treatments.
Keep exploring
The entities involved
-
GSK
British multinational pharmaceutical and biotechnology company
-
Gilead Sciences
American company
- FDA
Related events
- Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- FDA approval boosts the Korean drug industry, driving market attention for companies like SamChunDang Pharm.
- A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.
- Jack Leslie represents pharmaceutical firms like GSK and consulted for the Gates Foundation.
Coverage
Newest first; wire copies grouped- Unknown outlet